medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2011, Number 1

<< Back Next >>

Rev Mex Urol 2011; 71 (1)

Carcinoma de corteza suprarrenal, informe de un caso y revisión de la bibliografía

Vilchis-Cárdenas MA, López-Verdugo JF, Aragón-Tovar AR, Torres-Medina E, Saldaña-Guajardo MJ, García-Rodríguez MA, Castro-Duarte JC, Ignacio-Morales C

Language: Spanish
References: 54
Page: 47-56
PDF size: 444.78 Kb.


ABSTRACT

Patient is a 43-year-old man with oncologic genetic load: mother presented with breast cancer, father with prostate cancer, and sister with ovarian cancer. Patient has tenyear progression of high blood pressure controlled with angiotensin-converting enzyme inhibitor. Present illness of one-year progression, patient presented with diffuse postprandial abdominal pain with peaks of intensity in the epigastrium and right hypochondrium accompanied withvomiting. Patient was initially treated for peptic acid disease with no success. Physical examination did not produce relevant information. In studying pain, right adrenal mass was detected. Laboratory tests were normal. Ultrasound imaging revealed 9.9 x 6.8 cm right heterogeneous adrenal mass that was confirmed with tomography and magnetic resonance studies. Histopathological result of adrenal mass reported right adrenal carcinoma.


REFERENCES

  1. Brown-Séquard CE. Recherches experimentales sur la physiologie et la pathologie des capsules surrenales. Arch Gen Med 1856;2:385

  2. Biglieri EG, Kater CE, Mantero F. Adrenocortical forms of human hypertension. Hypertension: Pathophysiology, Diagnosis, and Management, nd Ed. New York. Raven Press;1995:pp.2145-62.

  3. New MI. Congenital adrenal hyperplasia: 21-Hydroxylase deficiency and 11β -hydroxylase deficiency in renal and adrenal tumors. Renal and Adrenal Tumors. Biology and Management. New ork: Oxford University Press;2003.

  4. Chulick RD, Brenna M. Adrenocortical carcinoma: Renal and adrenal tumors: Biology and management, UK Oxford University Press;2005.

  5. Menendez Calderon MJ, Casal F, Prieto J, Cacho L. Carcinoma suprarrenal. Análisis retrospectivo de cinco casos. An Med Interna 2006;23:533-6.

  6. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003;149:273-85.

  7. Plager JE. Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. Int Adv Surg Oncol 1984;7:329-53.

  8. Javadpour N, Woltering EA, Brennan MF. Adrenal neoplasms. Curr Probl Surg 1980;17:1–52.

  9. Muñoz-Casares FC, López-Cillero P, Delgado JB, et al. Carcinoma suprarrenocortical. Abordaje terapéutico en estadio avanzado. Cir Esp 2002;72:45-7.

  10. Novakovic K, Ersahin C, Picken M, et al: Malignant adrenal tumors. AUA Update Series 2004;23:241-247.

  11. Wajchenberg BL, Albergaria Pereira MA, Medonca BB. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711-36.

  12. Alexandria T Phan. Adrenal cortical carcinoma-Review of current knowledge and treatment practices. Hematol Oncol Clin North Am 2007;21:489-507.

  13. Fogt F, Vargas MP, Zhuang Z, Merino MJ. Utilization of molecular genetics in the differentiation between adrenal cortical adenomas and carcinomas. Hum Pathol 1998;29:518-21.

  14. Jaffe RB, Mesiano S, Smith R, et al. The regulation and role of fetal adrenal development in human pregnancy. Endocr Res 1998;24:919-26.

  15. Sullivan JG, Gohul M, Kinder B. Ectopic adrenocortical tissue found at groin exploration in children: Incidence in relation to diagnosis, age and sex. BJU Int 2005;95:407-10.

  16. Bornstein SR, Ehrhart-Bornstein M, Usadel H, et al. Morphological evidence for a close interaction of chromaffin cells with cortical cells within the adrenal gland. Cell Tissue Res 1991;265:1-9.

  17. Lindzey J, Korach KS. Steroid hormones in endocrinology: Basic and clinical principles. Endocrinology: Basic and clinical principles, Totowa, NJ: Humana Press; 1997:47-62.

  18. New MI. Congenital adrenal hyperplasia: 21-Hydroxylase deficiency and 11β-hydroxylase deficiency in renal and adrenal tumors. Renal and Adrenal Tumors. Biology and Management, New York: Oxford University Press;2003.

  19. Hubbard MM, Kulaylat MM, Amabumrad NN. Adrenocorticoids: physiology, regulation, function, and metabolism. Surgery of the Adrenal Glands, Philadelphia: JB Lippincott;1990.

  20. Liu Z, Siragy MM, Carey RM: Diagnostic tests of adrenal cortical and medullary function. Renal and Adrenal Tumors. Biology and Management, New York: Oxford University Press;2003.

  21. Manger WM, Gifford Jr. RW: Pheochromocytoma. Hypertension: pathophysiology, diagnosis and management, New York. Raven Press;1990.

  22. Bravo EL, Tagle R. Pheochromocytoma: State of the art and future prospects. Endocr Rev 2003;24:539-53.

  23. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001;92:11124.

  24. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N Engl J Med 1990;322:1195-201.

  25. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001;25:891-7.

  26. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003;169:5-11.

  27. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119:161-70.

  28. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (incidentaloma). Ann Intern Med 2003;138:424-9.

  29. Staren ED, Prinz RA. Selection of patients with adrenal incidentalomas for operation. Surg Clin North Am 1995;75:499-509.

  30. Barzon L, Boscaro M. Diagnosis and management of adrenal incidentalomas. J Urol 2000;163:398-407.

  31. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (‘‘incidentaloma’’). NIH Consens State Sci Statements 2002;;9:1-25.

  32. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996;200:743–7.

  33. Outwater EK, Siegelman ES, Huang AB, et al. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 1996;200:749–52.

  34. Yun M, KimW, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795–9

  35. Modified from Vaughn ED: Complications of adrenal surgery. Complications of Urologic Surgery: Prevention and Management, 3rd ed. Philadelphia, WB Saunders, 2001:363.

  36. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119:161– 70.

  37. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112:972–9.

  38. Dackiw AP, Lee JE, Gagel RF, et al. Adrenal cortical carcinoma. World J Surg 2001;25:914–26.

  39. Cobb WS, Kercher KW, Sing RF, et al. Laparoscopic adrenalectomy for malignancy. Am J Surg 2005;189:405–11.

  40. Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005;138:1078–85.

  41. Undre S, Munz Y, Moorthy K, et al: Robot-assisted laparoscopic adrenalectomy: Preliminary UK results. BJU Int 2004;93:357-9.

  42. Abraham J, Fojo T, Wood BJ. Radiofrequency ablation of metastatic lesions in adrenocortical cancer. Ann Intern Med 2000;133:312-3.

  43. Munver R, Sosa RE. Cryosurgery of the adrenal gland. Technol Cancer Res Treat 2004;3:181-5.

  44. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-201.

  45. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-26.

  46. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998;83:2194-200.

  47. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol. 1978;120:660-5.

  48. Ekici S, Ciancio G. Surgical management of large adrenal masses with or without thrombus extending into the inferior vena cava. J Urol 2004;172(Pt 1):2340-3.

  49. Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981;71:855-75.

  50. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-6.

  51. Wachenfeld C, Beuschlein F, Zwermann O, et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol 2001;145:335–41.

  52. Saeger W. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. Hum Pathol 2003;34:180–6.




2020     |     www.medigraphic.com